1[1]McCully KS, Am J. Vascular pathology of homocysteine implications for the pathogenesis of arteriosclerosis. Am J Pathology, 1969,56:111.
2[2]Coppla A, Davi G, De stefano V, et al. Homocyteine-thiolactone induces caspase-independent vascular endothelial cell death with apoptotic features.Apoptosis, 2000,5:403-411.
3[3]Cordoba-Porras A, Sanchez-Quesada JL, Gonzalez-Satre F, et al. A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patient with coronary artery disease. J Am Coll Cardiol,2001,37:1858-1863.
4[4]Dardik R, Varon D, Tamarin I, et al. Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells under flow condition:distict mechanisms of thrombogenicmodulation. Thromb Haemost, 2000, 83:338-344.
5[5]Coppola A, Davi G, De Stefano V, et al. Homocysteine, cnagulation, platelet function, and thrombosis. Semin Thromb Haemost,2000,26:243-254.
6[6]Kugiyama K, Sakamoto T, Miswui I, et al. Transferable lipids in oxidixed lowdensity lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res, 1993,73: 335-353.
7[7]Tokumura A, Sumida T, Toujima M, et al. Plate let-activating factor(PAF) -like oxidized phospholipids: relevance to atherosclerosis. Biofactors, 2000, 13: 29-33.
8[8]Weber C, Erz W, Weber KS, et al. Effects of oxidized low density lopoprotein,lipid mediators and station on vascular cell interaction. Clin Cham Lab Med,1999,37:243-251.
9[9]Cordoba-Porras, Sanchez-Quesada JL, Gonzalez-Sastre F, et al. Susceptibility of plasma low-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia. J Mol MED, 1996,74:771-776.
